Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Dermatologic 1

Conditions

Neoplasms 2Leukemia 2Brain Neoplasms 2Urinary Bladder Neoplasms 1Respiratory Sounds 1Prostatic Neoplasms 1Pre-Eclampsia 1Postoperative Complications 1Parkinson Disease 1Neuroendocrine Tumors 1Neuroblastoma 1Myelodysplastic Syndromes 1Musculoskeletal Pain 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma 1Liver Cirrhosis 1Lewy Body Disease 1Hypoxia 1Hodgkin Disease 1Hemorrhage 1Edema 1Dyspnea, Paroxysmal 1Dyspnea 1Drug-Related Side Effects and Adverse Reactions 1Congenital Hyperinsulinism 1Breast Neoplasms 1Advanced Solid Malignancies 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 92Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 52Doxorubicin 50trametinib 47atezolizumab 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Neoplasms × Furosemide × Clear all
NCT05470283 2026-04-16

Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
21 enrolled
Dermatologic

Melanoma, Neoplasms

NCT02501213 2019-05-16

Evaluation of the Efficacy of Diuretics for Symptomatic Malignant Ascites Episodes in Advanced Stage of Cancer (DIASC)

Centre Oscar Lambret

Phase 2 Terminated
14 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡